| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3398392 | Clinical Microbiology and Infection | 2006 | 4 Pages |
Abstract
ABSTRACTVancomycin serum concentrations were determined for 1737 patients treated with either 2 × 1 g of vancomycin or 4 × 500 mg daily (780 patients), according to current nomograms, or by continuous infusion (957 patients) with a loading dose (1 g) and a total of 2–6 g daily. Trough serum concentrations were determined after 36–48 h. Adequate serum levels for the treatment of a normal methicillin-resistant Staphylococcus aureus (MRSA) and a glycopeptide-intermediate S. aureus (GISA) were observed in 81% and 20.9% of patients, respectively. The data support theoretical arguments that higher and more sustained serum levels of vancomycin, obtained by continuous infusion, may enhance clinical efficacy.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
M.D. Kitzis, F.W. Goldstein,